Why Single-Substance Addiction Treatment No Longer Works
For decades, addiction treatment followed a simple formula: identify the drug and treat the drug. If someone struggled with heroin, they went to a heroin program. If alcohol was the issue, they entered alcohol treatment. That single-substance model shaped how many providers approached substance use disorder care.
But the reality of polysubstance use in 2026 looks very different. Today, many people with opioid use disorder are using multiple substances, sometimes intentionally and sometimes because the drug supply is contaminated. As a result, modern addiction treatment is shifting toward integrated, person-centered care that addresses more than one substance at a time.
A recent presentation by the SAMHSA-funded Opioid Response Network, led by Fernando Pena, laid out just how dramatically the landscape has shifted and what it means for the people and communities affected.
The Numbers Behind Polysubstance Use
Consider this: 81% of people who use opioids report using multiple substances in a given month. When labs test samples that contain fentanyl, 90% of the time they also find other drugs mixed in, with deaths involving both fentanyl and stimulants like methamphetamine increased 60-fold between 2010 and 2021.
These aren’t just statistics, they represent real people navigating an increasingly dangerous and unpredictable drug supply. Many don’t even know what they’re consuming. Someone who believes they’re using cocaine or methamphetamine may unknowingly be exposed to fentanyl, a synthetic opioid roughly 50 times more potent than heroin. The contamination of the drug supply has made polysubstance use something that happens to people, not just something people choose.
Why People Use Multiple Substances
Of course, intentional mixing happens too and for understandable reasons. People combine substances to balance a high, manage a comedown, or cope with pain, anxiety, trauma, and sleeplessness. When mental health care is hard to access, due to cost, stigma, or long wait times, substances can become a person’s primary coping tool. Research shows that nearly 67% of people with opioid use disorder also have a co-occurring mental health condition, including depression, PTSD, and bipolar disorder.
There’s also a troubling acceleration happening. In the 1990s, the average gap between someone’s first and second substance was nearly seven years. Today, it’s just a year and a half. People are being exposed to more drugs, more quickly, in a supply chain that’s more volatile than ever.
Why Traditional Addiction Treatment Falls Short
If someone walks into a treatment setting and is asked only about their “primary substance,” we’re likely missing about 80% of the clinical picture. Traditional screening tools weren’t designed for this complexity. Patients may not know what they’ve consumed. Symptoms of withdrawal from one drug can look identical to intoxication from another. And standard urine tests can’t detect newer substances like xylazine or netazines that are increasingly showing up in the drug supply.
Effective assessment today means asking different questions, not just “what do you use?” but “do you use substances together or separately?”, “what was happening in your life when you started?”, and “if you were going to quit, what would be the hardest part?” These questions open the door to understanding the full picture, not just the most visible piece.
Integrated Addiction Treatment for Polysubstance Use
What does better treatment look like? It starts with meeting people where they are literally and figuratively.
Medication-assisted treatment (MAT) remains a first-line approach for opioid use disorder, but in a polysubstance context, medication choices require more nuance. Buprenorphine, methadone, and naltrexone each have different benefits and risks depending on what else a person is using. Combining opioids with benzodiazepines, for example, significantly increases the risk of respiratory depression and death. There’s no one-size-fits-all medication treatment must be individualized.
Beyond medication, evidence-based therapies like cognitive behavioral therapy (CBT), motivational interviewing, and contingency management have shown real promise. CBT helps people identify triggers specific to each substance they use. Motivational interviewing builds a person’s own desire for change rather than imposing it. And contingency management offering tangible incentives for staying on track has proven effective at supporting sustained engagement with treatment.
But perhaps the most important shift is recognizing that no single clinician can manage polysubstance complexity alone. Effective care requires teams: prescribers managing medications, counselors providing therapy, psychiatrists addressing co-occurring mental health conditions, social workers helping with housing and employment, and peer specialists offering the irreplaceable value of lived experience.
The Role of Trauma-Informed Care and Person-First Language
Between 50% and 70% of people in substance use treatment have a history of trauma. For many, polysubstance use is a way of managing the emotional fallout from experiences like abuse, violence, or loss. That’s why trauma-informed care built on principles of safety, trust, peer support, collaboration, and empowerment isn’t optional, it’s essential.
Even the language we use matters. Saying “person with opioid use disorder” instead of “addict,” or “returned to use” instead of “relapsed,” may seem like a small change. But for someone carrying deep shame about their substance use, that shift in language can be the difference between feeling judged and feeling seen.
What Comes Next for Addiction Treatment
The path forward isn’t simple, but it is clear. We need comprehensive screening that accounts for multiple substances. We need treatment that integrates mental health care, housing support, peer connection, and medication, not as separate tracks, but as a unified plan for everyone. We need to approach every interaction with the belief that recovery is possible, even when the road is long.
As Pena put it in his closing remarks: “Polysubstance use is complex. But so is recovery. With integrated treatment, trauma-informed care, and hope in every interaction, you help people rebuild their lives.”
That hope isn’t naive, it’s evidence based and it’s something every community can choose to invest in.